<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1291">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01789775</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.40174</org_study_id>
    <nct_id>NCT01789775</nct_id>
  </id_info>
  <brief_title>Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <oversight_info>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Russia: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema
      associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once
      daily is more efficacious than vehicle and provides an acceptable safety profile in the
      treatment of facial erythema associated with rosacea
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite Success Assessment (CEA) and Patient Self Assessment(PSA).</measure>
    <time_frame>Day 29</time_frame>
    <safety_issue>No</safety_issue>
    <description>Composite Success is defined as 1-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Success Assessment (CEA) and Patient Self Assessment(PSA).</measure>
    <time_frame>D1</time_frame>
    <safety_issue>No</safety_issue>
    <description>30 Minutes Effect is defined as 1 grade improvement on CEA and PSA at 30 minutes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>CD07805/47 gel Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CD07805/47 gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: CD07805/47 gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: CD07805/47 gel</intervention_name>
    <arm_group_label>CD07805/47 gel Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD07805/47 gel Placebo</intervention_name>
    <arm_group_label>CD07805/47 gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male or female who is at least 18 years of age or older.

          2. A clinical diagnosis of facial rosacea.

          3. A Clinician Erythema Assessment (CEA) score of greater than or equal to 3 at
             Screening and at Baseline/Day 1 (prior to the study drug application).

          4. A Patient Self Assessment (PSA) score of greater than or equal to 3 at Screening and
             at Baseline/Day 1 (prior to the study drug application).

        Key Exclusion Criteria:

          1. More than 20 facial inflammatory lesions of rosacea

          2. Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated
             rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses
             that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial
             keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic
             telangiectasia.

          3. Current treatment with monoamine oxidase (MAO) inhibitors, barbiturates, opiates,
             sedatives, systemic anesthetics, or alpha agonists.

          4. Less than 3 months stable dose treatment with tricyclic anti depressants, cardiac
             glycosides, beta blockers or other antihypertensive agents.

          5. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic
             hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal
             or hepatic impairment, scleroderma, Sj√∂gren's syndrome, or depression.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Nice</city>
        <zip>06</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galderma Investigational Site</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Russian Federation</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 14, 2014</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <firstreceived_results_date>October 14, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CD07805/47 Gel Placebo</title>
          <description>Placebo
Drug: CD07805/47 gel</description>
        </group>
        <group group_id="P2">
          <title>CD07805/47 Gel</title>
          <description>Intervention: Drug: CD07805/47 gel
CD07805/47 gel Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CD07805/47 Gel Placebo</title>
          <description>Placebo
Drug: CD07805/47 gel</description>
        </group>
        <group group_id="B2">
          <title>CD07805/47 Gel</title>
          <description>Intervention: Drug: CD07805/47 gel
CD07805/47 gel Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="55"/>
                <measurement group_id="B2" value="57"/>
                <measurement group_id="B3" value="112"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="44.9" spread="12.1"/>
                <measurement group_id="B2" value="43.2" spread="10.8"/>
                <measurement group_id="B3" value="44.0" spread="11.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="51"/>
                <measurement group_id="B2" value="56"/>
                <measurement group_id="B3" value="107"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
                <measurement group_id="B2" value="41"/>
                <measurement group_id="B3" value="81"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="31"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Russian Federation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="46"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="92"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Sweden</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Composite Success Assessment (CEA) and Patient Self Assessment(PSA).</title>
        <description>30 Minutes Effect is defined as 1 grade improvement on CEA and PSA at 30 minutes.</description>
        <time_frame>D1</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Composite Success Assessment (CEA) and Patient Self Assessment(PSA).</title>
        <description>Composite Success is defined as 1-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).</description>
        <time_frame>Day 29</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>CD07805/47 Gel Placebo</title>
            <description>Placebo
Drug: CD07805/47 gel</description>
          </group>
          <group group_id="O2">
            <title>CD07805/47 Gel</title>
            <description>Intervention: Drug: CD07805/47 gel
CD07805/47 gel Placebo</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="55"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Composite Success Assessment (CEA) and Patient Self Assessment(PSA).</title>
            <description>Composite Success is defined as 1-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>D29 Hour 3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="48"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>D29 Hour 5</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>D29 Hour 7</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>D29 Hour 9</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                  <measurement group_id="O2" value="39"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CD07805/47 Gel Placebo</title>
          <description>Placebo
Drug: CD07805/47 gel</description>
        </group>
        <group group_id="E2">
          <title>CD07805/47 Gel</title>
          <description>Intervention: Drug: CD07805/47 gel
CD07805/47 gel Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angiodema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Galderma CPM</name_or_title>
      <organization>Galderma R&amp;D</organization>
      <phone>00 33 4 93 95 70 70</phone>
      <email>clinicaltrials@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
